• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Benchling Raises $50M to Scale Life Sciences R&D Platform & Fuel Biotech Innovations

by Jasmine Pennic 05/28/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Today, life sciences R&D cloud platform Benchling announced a $50M Series D raise led by Alkeon and joined by new investors Spark Capital, Lux Capital and ICONIQ Partners, as well as existing investors Thrive Capital and Benchmark. 

– This funding will help Benchling expand its product suite, providing vital collaboration tools for life science researchers to help embrace the complexity of biology and find breakthroughs faster.


Benchling, the leading life sciences R&D cloud platform, announced it closed $50 million in Series D funding led by Alkeon and joined by new investors Spark Capital, Lux Capital, and ICONIQ Partners, as well as existing investors Thrive Capital and Benchmark. The round comes at one of the most pivotal moments for the biotechnology industry as companies race to deliver diagnostics, therapeutics, and vaccines for COVID-19, while advances such as CRISPR and lab robotics continue to fuel breakthroughs in medicine, food, and agriculture, energy and materials. Benchling will use the investment to build advanced product capabilities, expand its international presence, and drive adoption across leading R&D organizations, bringing the power of modern-day software to drive the rapid transformation of the life sciences industry.

Replacing Outdated Pen and Paper Processes

Life science R&D has become incredibly complex — from the molecules to the processes to the multi-dimensional data. Until Benchling, there had been no end-to-end, purpose-built SaaS application to enhance, streamline, and drive collaboration across R&D teams.

Founded in 2012, Benchling is helping the next generation of scientists make breakthrough discoveries faster than ever before. Replacing outdated pen and paper processes, Benchling offers unified R&D solutions purpose-built for biotech, including Notebook, Molecular Biology, Registry, Inventory, and Request & Workflow Management.

Recent Traction/Milestones

Since launching in 2012, more than 230,000 scientists and 1,000 R&D organizations have adopted Benchling’s cloud platform to centralize massively complex experimental datasets and optimize R&D processes. Benchling doubled its customer base over the past year across industries ranging from pharmaceuticals and fuels to agriculture and food. Scientists report that the solution doubles R&D productivity, with customers at the forefront of COVID-19 research, such as Gilead Sciences, Regeneron Pharmaceuticals and Mammoth Biosciences, seeing usage soar 54% since the start of the pandemic.

So far this year, Benchling has launched several product enhancements, including Benchling for Lab Automation to help companies maximize lab automation investments, and Benchling Insights, which gives life scientists the ability to query, visualize and collaborate around complex biological data.

“Due to the COVID-19 pandemic, biotechnology is in the global spotlight like never before. We are proud that so many of our customers are relying on Benchling to develop diagnostics, treatments and vaccines with speed and precision,” said Saji Wickramasekara, CEO and founder of Benchling. “Rapidly solving COVID-19 is just the start of what will solidify this as the century of biotech. This funding enables us to bring that same speed to life science as a whole, no matter the research area – oncology, food and agriculture, energy, or materials. In particular, with our upcoming products to support chemistry-based R&D and chemically-modified biomolecules, Benchling will soon become a singular solution for all of life science.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |